CN107184591A - One kind promotes postoperative wound healing ointment - Google Patents
One kind promotes postoperative wound healing ointment Download PDFInfo
- Publication number
- CN107184591A CN107184591A CN201710420461.8A CN201710420461A CN107184591A CN 107184591 A CN107184591 A CN 107184591A CN 201710420461 A CN201710420461 A CN 201710420461A CN 107184591 A CN107184591 A CN 107184591A
- Authority
- CN
- China
- Prior art keywords
- wound healing
- ointment
- postoperative wound
- robinin
- albiflorin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
Abstract
A kind of promotion postoperative wound healing ointment of the invention, is made up of active component and pharmaceutic adjuvant, and described active component is robinin and albiflorin, and the preferably weight ratio of robinin and albiflorin is 1 10：1.The medicine of the present invention promotes postoperative wound healing effect good.
Description
Technical field
The invention belongs to technical field of medicine, and in particular to one kind promotes postoperative wound healing ointment.
Background technology
Infection of incisional wound is one of Post operation common complication, and its consequence is otch delayed union, may occur disruption of wound,
Even cause systemic infection.The pathogen of infection is from internal organs or original infection focus such as the external world, skin, enteron aisles.
Infection often occurs first around hypodermis and suture.Therefore, a kind of postoperative wound of the promotion of better efficacy is researched and developed
Mouth healing ointment is particularly important.
The content of the invention
In view of the deficiencies in the prior art, it is an object of the invention to promoted by the research of a large amount of internal and external tests there is provided one kind
Enter postoperative wound healing ointment.
The object of the present invention is achieved like this：
One kind promotes postoperative wound healing ointment, is made up of active component and pharmaceutic adjuvant, described active component is
Robinin and albiflorin.
The weight ratio of the promotion postoperative wound healing ointment, robinin and albiflorin is 1-10：1.
The weight ratio of the promotion postoperative wound healing ointment, robinin and albiflorin is 3-5：1.
The promotion postoperative wound healing ointment, ointment is made by the component of following parts by weight in it：
The promotion postoperative wound healing ointment, described emulsifying agent is selected from stearic acid, single stearic acid glycerine lipoprotein and told
The one or more of temperature 80.
Compared with prior art, studied and found by animal experiment, ointment joint antibiotic of the invention is cured in otch
Effect in terms of conjunction is better than model control group, and the adhesion degree of uterus and surrounding tissue will significantly be lighter than positive controls and mould
Type control group, the ointment of this prompting present invention can effectively facilitate wound healing, prevent abdominal cavity adhesion.Especially, it is of the invention
Presentation belly muscle layer more than the drug combination group of ointment added with antibiotic and state of the skin without adhesion, and positive controls stomach wall flesh
Slight adhesion, easily peelable state is presented between layer and skin, and the extension of this state over time can further intensify,
Form the adhesion being not easily stripped.The application of the ointment of this prompting present invention has the effect for reducing postoperative tissue adhesion.
Embodiment
Form is described in further detail again to the above of the present invention by the following examples, but should not manage this
The scope solved as above-mentioned theme of the invention is only limitted to following embodiment, and all technologies realized based on the above of the present invention are equal
Belong to the scope of the present invention.
The preparation of the compound ointment agent of embodiment 1
Ointment prescription：
Preparation technology：First stearic acid is heated in water-bath and dissolved, atoleine is added and is heated to 75 DEG C ± 2 DEG C and protects
Hold, form oil phase；Robinin, albiflorin are dissolved in 1,2-PD and deionized water, Tween 80, anti-corrosion is then added
Agent, is sufficiently stirred for and is heated to 75 DEG C ± 2 DEG C and keeps, and forms aqueous phase；Finally the slow stream of oil phase is added in aqueous phase, side edged
Stir, until condensation, produces ointment.
The preparation of the compound ointment agent of embodiment 2
Ointment prescription：
Preparation technology：First single stearic acid glycerine lipoprotein is heated in water-bath and dissolved, atoleine is added and is heated to 75 DEG C
± 2 DEG C and keep, form oil phase；Robinin, albiflorin are dissolved in 1,2-PD and deionized water, then adds and tells
Temperature 80, preservative, are sufficiently stirred for and are heated to 75 DEG C ± 2 DEG C and keep, and form aqueous phase；The slow stream of oil phase is finally added into aqueous phase
In, side edged is stirred, until condensation, produces ointment.
The preparation of the compound ointment agent of embodiment 3
Ointment prescription：
Preparation technology：First single stearic acid glycerine lipoprotein is heated in water-bath and dissolved, atoleine is added and is heated to 75 DEG C
± 2 DEG C and keep, form oil phase；Robinin, albiflorin are dissolved in 1,2-PD and deionized water, then adds and tells
Temperature 80, preservative, are sufficiently stirred for and are heated to 75 DEG C ± 2 DEG C and keep, and form aqueous phase；The slow stream of oil phase is finally added into aqueous phase
In, side edged is stirred, until condensation, produces ointment.
Comparative example 1
Ointment prescription：The preparation of robinin ointment
Preparation technology：Be the same as Example 1.
Comparative example 2：The preparation of albiflorin ointment
Ointment prescription：
Preparation technology：Be the same as Example 1.
The influence of embodiment 4, the present invention to caesarean birth rat wound healing
60 oestrus female sd inbred rats, are randomly divided into following 5 groups：Model control group (gavage 10mL/kg physiological saline),
Positive controls (160,000 units of intraperitoneal injection Benzylpenicillin sodium salt/kg), the robinin ointment group (list of intraperitoneal injection Benzylpenicillin sodium salt 160,000
Position/kg and external application comparative example 1 of the present invention ointment), (intraperitoneal injection Benzylpenicillin sodium salt 160,000 is single for albiflorin ointment group
Position/kg and external application comparative example 1 of the present invention ointment), drug combination group (intraperitoneal injection Benzylpenicillin sodium salt 160,000 units/kg and
The ointment of the external application embodiment of the present invention 3), every group of l2 is only.After whole rats are become pregnant, in pregnant 2l days under 10% chloral hydrate anesthesia
Row cesarean section.Abdominal cavity is opened after sterilization, 0.5cm otch is cut, with eye in exposure both sides uterus in the stage casing in both sides uterus respectively
Section's Smooth forceps takes out newborn mouse and placenta one by one, sutures uterine incision, and uterus also received into abdominal cavity, and muscle layer and skin are sutured respectively
Skin, applies to be put into after 2% tincture of iodine and newly changes in litter box, bedding and padding thicken, and it is that rat is warming that laboratory temperature, which is kept for 26~27 DEG C,.Medication
Time is 7 days.Organize the daily otch of rat separately and apply 2% tincture of iodine 1 time.
Investigate the following index of each group rat：(1) abdominal incision healing state；(2) belly muscle layer (can with skin adhesion situation
It is divided into no adhesion, easily peelable slight adhesion, slight adhesion, 4 grades of severe adhesion)；(3) uterus (can with surrounding tissue adhesion situation
It is divided into no adhesion, slight adhesion, 3 grades of severe adhesion).
The abdominal incision healing state of table 1 compares
The belly muscle layer of table 2 is compared with skin adhesion situation
Compared with surrounding tissue adhesion situation in the uterus of table 3
Abdominal incision healing state is relatively shown in Table 1.Compare between wound healing situation group, positive controls, drug combination group
Wound healing situation is significantly better than model control group.Belly muscle layer is compared with skin adhesion situation is shown in Table 2.Belly muscle layer and skin
Compare between adhesion situation group, the adhesion of drug combination group otch will significantly be lighter than positive controls and model control group.Uterus with
Surrounding tissue adhesion situation is relatively shown in Table 3.Compared between uterus and surrounding tissue adhesion situation group, positive controls, drug combination
The uterus of group and the adhesion degree of surrounding tissue are significantly lower than model control group.The effect of drug combination group is better than robinin
Group and albiflorin group, illustrate that robinin and albiflorin have synergy.
Found by experimental study, ointment of the invention combines effect of the antibiotic in terms of wound healing and is better than mould
The adhesion degree of type control group, uterus and surrounding tissue will significantly be lighter than positive controls and model control group, and this points out this to send out
Bright ointment can effectively facilitate wound healing, prevent abdominal cavity adhesion.Especially, the joint of ointment added with antibiotic of the invention
Belly muscle layer and state of the skin without adhesion is presented more medication group, and is presented between positive controls abdominal muscle and skin light
Adhesion, easily peelable state are spent, and the extension of this state over time can further intensify, and form the adhesion being not easily stripped.
Claims (5)
1. one kind promotes postoperative wound healing ointment, it is made up of active component and pharmaceutic adjuvant, it is characterised in that：Described work
Property composition be robinin and albiflorin.
2. promote postoperative wound healing ointment according to claim 1, it is characterised in that：Robinin and albiflorin
Weight ratio is 1-10：1.
3. promote postoperative wound healing ointment according to claim 1, it is characterised in that：Robinin and albiflorin
Weight ratio is 3-5：1.
4. promotion postoperative wound healing ointment according to claim 1 or claim 2, it is characterised in that：It is by following parts by weight
Ointment is made in component：
5. promote postoperative wound healing ointment according to claim 4, it is characterised in that：Described emulsifying agent is selected from tristearin
The one or more of acid, single stearic acid glycerine lipoprotein and Tween 80.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710420461.8A CN107184591A (en) | 2017-06-07 | 2017-06-07 | One kind promotes postoperative wound healing ointment |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710420461.8A CN107184591A (en) | 2017-06-07 | 2017-06-07 | One kind promotes postoperative wound healing ointment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107184591A true CN107184591A (en) | 2017-09-22 |
Family
ID=59876337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710420461.8A Withdrawn CN107184591A (en) | 2017-06-07 | 2017-06-07 | One kind promotes postoperative wound healing ointment |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107184591A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102125575A (en) * | 2010-01-19 | 2011-07-20 | 张作光 | Application of albiflorin in resisting Parkinson's disease |
| CN102491964A (en) * | 2011-12-11 | 2012-06-13 | 卞毓平 | Method for extracting acacetin from chrysanthemum |
-
2017
- 2017-06-07 CN CN201710420461.8A patent/CN107184591A/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102125575A (en) * | 2010-01-19 | 2011-07-20 | 张作光 | Application of albiflorin in resisting Parkinson's disease |
| CN102491964A (en) * | 2011-12-11 | 2012-06-13 | 卞毓平 | Method for extracting acacetin from chrysanthemum |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lee et al. | Transoral periosteal thyroidectomy: cadaver to human | |
| Newman | Bovine cesarean section in the field | |
| Choi et al. | Surgical outcomes of a new approach to laparoscopic myomectomy: single-port and modified suture technique | |
| Hegner | A history of thyroid surgery | |
| Modi et al. | Laparoscopic transplantation following transvaginal insertion of the kidney: description of technique and outcome | |
| WO2015183230A9 (en) | Composition based on a stabilized solution of active ingredients | |
| CN107184591A (en) | One kind promotes postoperative wound healing ointment | |
| Murugesan et al. | Comparative study on midline and lateral flank approaches for ovariohysterectomy in cats | |
| Zhang et al. | Effect of high-intensity focused ultrasound ablation on endometriosis of the abdominal wall | |
| Granados et al. | Canine laparoscopic ovariectomy using two 3-and 5-mm portal sites: A prospective randomized clinical trial | |
| JP2016175884A (en) | External agent for diffuse neurofibroma | |
| Pye et al. | Endoscopic salpingohysterectomy of juvenile cockatiels (Nymphicus hollandicus) | |
| Demiral et al. | Comparison of LigaSure and the Conventional Method in Total Thyroidectomy: A Single Surgeon s Experience and Review of the Literature that LigaSure is not superior to Suture Ligation in Total Thyroidectomy | |
| Li et al. | A new minimally invasive method of transverse aortic constriction in mice | |
| RU2337704C1 (en) | Method of postsurgery rehabilitation of fishes | |
| Azizunnesa et al. | Spaying as a tool for birth control: A case report | |
| Ajeel et al. | Caesarean section in ruminants referred to the AL-Muthanna Veterinary Hospital | |
| de Campos Martins et al. | Cholecystectomy by single trocar access (SITRACC): the first multicenter study | |
| Islam et al. | Successful Cesarean and Sterilization in Bitch First Case Report at University of Rajshahi, Bangladesh | |
| Bel et al. | Prefemoral oophorectomy in red eared terrapins (Trachemys scripta elegans). | |
| Ghanbari et al. | Pfannenstiel versus Maylard incision for gynecologic surgery: a randomized, double-blind controlled trial | |
| RU2606494C1 (en) | Method of conservative myomectomy in pregnant women | |
| Wolfsdorf | Management of twins in the mare | |
| Ciprian et al. | Appendectomy single incision laparoscopic surgery (sils)-our early experience | |
| RU2580660C1 (en) | Method for elimination of through defect of nose |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170922 |